Jun 18, 2026
15 MIN READ

Ozempic and Blood Work: What Your Tests Really Show

Semaglutide therapy requires regular blood work to track your metabolic response and ensure safe dosing. Understanding your lab results helps you and your provider optimize your weight loss treatment plan.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 18, 2026
15 MIN READ

ozempic and blood work: what your tests really show — PlexusDx GLP-1 education

Last reviewed: June 19, 2026

Last updated: June 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

When you start semaglutide therapy, blood work becomes a critical tool for monitoring your body's response to the medication. GLP-1 receptor agonists like semaglutide affect glucose metabolism, pancreatic function, and inflammation markers—changes that show up in your lab results. Regular testing helps your healthcare provider adjust your treatment and catch any emerging concerns early.

Blood Glucose and Insulin Levels During Semaglutide Therapy

Semaglutide lowers blood sugar by increasing insulin secretion when glucose rises and slowing gastric emptying. Your fasting glucose and hemoglobin A1C levels typically decline within weeks of starting treatment. A1C reflects your average blood sugar over three months, making it the gold standard for measuring long-term metabolic control.

Insulin levels often drop on semaglutide because your pancreas doesn't need to work as hard to manage glucose. This improvement in insulin sensitivity is one reason semaglutide produces weight loss even in people without diabetes. Your provider may order fasting insulin tests to track this shift and confirm your metabolic health is improving.

Liver and Kidney Function Tests on GLP-1 Therapy

Liver enzymes (AST, ALT) and kidney function markers (creatinine, eGFR) require baseline testing and periodic monitoring during semaglutide treatment. These organs process the medication and handle changes in metabolic load, so tracking their function ensures safety. Most patients maintain normal liver and kidney values, but pre-existing conditions may require more frequent checks.

Your provider will establish baseline kidney function before starting therapy because semaglutide-related weight loss can affect hydration and electrolyte balance. If your eGFR drops significantly or liver enzymes rise beyond normal ranges, your provider may adjust your dose or investigate underlying causes. PlexusDx recommends initial blood work within one month of starting semaglutide, then every 3–6 months during treatment.

Pancreatic Markers and Lipase Monitoring

Lipase is an enzyme produced by your pancreas that aids fat digestion. Elevated lipase can signal pancreatitis, a rare but serious side effect associated with GLP-1 medications. Your baseline lipase test establishes your normal range; any significant increase warrants immediate medical evaluation and possible dose adjustment or discontinuation.

Amylase, another pancreatic enzyme, is sometimes checked alongside lipase for complete pancreatic assessment. Clinical trials of semaglutide show pancreatitis occurs in fewer than 1% of patients, but those with a history of pancreatitis or gallbladder disease face higher risk. Your provider will use baseline pancreatic labs and symptom reports to guide ongoing monitoring decisions.

Lipid Panel Changes and Cardiovascular Health

Semaglutide typically improves your lipid panel by lowering LDL cholesterol and triglycerides while raising protective HDL cholesterol. These cardiovascular benefits develop gradually over months as weight loss accumulates and metabolic inflammation decreases. Your baseline lipid panel allows your provider to quantify these improvements and adjust statin or other cardiac medications if needed.

Triglycerides often fall most dramatically in the first 8–12 weeks of semaglutide therapy, reflecting improved fat metabolism and reduced caloric intake. Some patients see LDL reduction of 10–20%, which compounds the cardiovascular benefits of weight loss itself. Lipid testing every 3–6 months tracks these gains and confirms semaglutide's cardioprotective effects alongside weight reduction.

How PlexusDx Uses Genetics to Personalize Your Monitoring Plan

PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways and 150+ genetic insights to predict how your body responds to semaglutide and other GLP-1 compounds. Variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) influence your appetite regulation, weight loss trajectory, and metabolic marker response. This genetic roadmap helps your provider anticipate which lab markers to watch most carefully and tailor your treatment plan.

Patients with specific genetic profiles may show faster glucose improvement, earlier lipid changes, or different side effect patterns. The Precision Peptide Genetic Test ($99 add-on after your first month of treatment) identifies these individual variations so your monitoring schedule matches your unique physiology. Combined with regular blood work, genetic insights empower you and your provider to optimize semaglutide therapy from the start.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How often should I get blood work while taking semaglutide?

PlexusDx recommends baseline blood work before starting semaglutide, follow-up testing at one month, and then every 3–6 months during treatment. Your provider may order more frequent testing if you have pre-existing liver, kidney, or pancreatic disease. Regular monitoring ensures your dose is safe and effective for your unique metabolism.

Will semaglutide improve my A1C and blood sugar?

Yes—semaglutide typically lowers fasting glucose within days and reduces A1C by 0.5–1.5 percentage points within 12 weeks, depending on your baseline level and genetics. This improvement reflects better insulin secretion, slower digestion, and improved insulin sensitivity. Your A1C test three months into treatment shows the full benefit and guides any dose adjustments.

What if my liver enzymes go up during semaglutide treatment?

Mild, temporary enzyme elevations can occur during rapid weight loss as your liver processes fat stores. However, significant or sustained increases require medical evaluation to rule out hepatitis or other liver disease. Your provider will review your test trends and may order additional imaging or specialist consultation if enzyme patterns concern them.

Is it safe to start semaglutide if I have a history of pancreatitis?

Patients with prior pancreatitis face elevated risk with GLP-1 therapy and should have detailed conversations with their provider before starting. Baseline lipase and amylase tests establish your pancreatic baseline, and very close monitoring is essential during treatment. Some providers avoid GLP-1s in this population; others use cautious dosing with frequent pancreatic marker checks.

How does PlexusDx personalize my treatment based on blood work and genetics?

PlexusDx combines your baseline lab results with Precision Peptide Genetic Test findings to predict your response to semaglutide across 14 metabolic pathways. Your genetic variants in GLP1R, GIPR, FTO, and MC4R influence how quickly your glucose, lipids, and weight respond to therapy. This personalized insight helps your provider select the right starting dose and anticipate your monitoring priorities—all while keeping your semaglutide injection flat-rate pricing at just $149/month.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves